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Due  to the  plethora  of  nanomaterials  being  manufactured,  it is  crucial  that  their  effects  on  human  health
are  understood.  It  is not  feasible  to assess  the  safety  of all  nanomaterials  using  animal-based  toxicity
tests.  There  are also  scientiﬁc,  business,  legislative  and  ethical  drivers  to reconsider  the  use  of  such
toxicity  tests.  Utilising  non-traditional  methods  has the  potential  to  improve  the  human  relevance  of
nanosafety  assessment,  reduce  the numbers  of  animals  that  are  used,  and  shift the  paradigm  to  a ‘21steywords:
Rs
lternative approaches
anotoxicology
anosafety
egulatory testing
century’  approach  that exploits  recent  scientiﬁc  and  technological  advances.  This  article  considers  how
application  of  the  3Rs principles  can  be  used  as a framework  to  support  and  guide  this  paradigm  shift  in the
short,  medium  and  long-term.  Bringing  the community  together  to  facilitate  the  transition  is necessary
to  ensure  that  tangible  impacts  are  made  on  the  efﬁciency  and  robustness  of  the  nanosafety  assessment
process.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDThere are numerous advantages of utilising manufactured nano-
aterials over their bulk chemical counterparts, due to their unique
hysiochemical properties. Over the last decade there has been a
otable rise in nanomaterial development and production within a
ast array of different applications. Nevertheless, concerns remainPlease cite this article in press as: N. Burden, et al., The 3Rs as a framewo
Nano Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.06.007
egarding their potential impact on human health. Science-led
fforts are needed to understand the genuine effects of nanoma-
erial exposure and ensure that health protection goals are met.
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Whole organisms, particularly rodents, continue to be the pre-
ferred test system for assessing the hazards of nanomaterials to
humans. This is mainly because they capture the site of admin-
istration, systemic distribution and the target tissues. Due  to the
potentially vast number of nanomaterials being marketed, regula-
tory toxicity testing could use large numbers of animals. The studies
can be technically demanding and relatively long in duration. Gen-
erating in vivo data for each nanomaterial is therefore not practical
or sustainable. There has been a great deal of discussion within
the ﬁeld in recent years around whether traditional methods are
the best way  to assess nanomaterial safety, and the need to ensure
that the data generated bears relevance to humans. There are also
business, ethical and legislative motivations to re-evaluate the use
of animal toxicity tests. For example, there have been recent geo-rk to support a 21st century approach for nanosafety assessment,
graphical bans on the testing of cosmetic ingredients in animals
and the marketing of products containing ingredients that have
been tested on animals.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Opportunities to align the 3Rs principles with improved approaches for nanosafety assessment in the short, medium and long-term.
Timeframe Opportunities to align with the 3Rs
Short-term (0–5 years) • Using short-term studies (e.g. short-term inhalation studies, [2]) as early tier tests. This would determine whether further
sub-chronic and chronic toxicity tests need to be carried out. Short-term studies could also be used as a tool to group substances for
read-across purposes, and thus reduce the number of 90 day regulatory in vivo studies required. Toxicokinetic analyses could also
be  incorporated into short-term studies, to inform dose setting and reﬁne subsequent chronic in vivo studies by ensuring high
doses are only administered where necessary.
•  Combining several endpoints within studies. This could include determining toxicity at both the exposure site (e.g. lungs) and
secondary target site (e.g. liver) as well as carrying out toxicokinetic assessments, to maximise the amount of information obtained
from  each study (e.g. see [3]).
•  Increasing consideration of exposure when designing in vitro and in vivo studies. For example, improving the relevance of
toxicology studies to the likely routes of exposure within human risk scenarios. This will help when applying tiered approaches,
which can be used to prioritise or waive testing.
•  Adaptation of existing in vitro test systems to facilitate nanosafety assessment and progress currently available nano-relevant
in  vitro assays towards formalised validation (e.g., see [4]). Efforts should be made to redress the problems associated with the
relevance and reliability of existing in vitro assays for nanomaterial testing.
Medium-term (5–10 years) • Leveraging existing information to prioritise the nanomaterials taken forward into animal studies. This could be achieved through
grouping approaches. Effective grouping of nanomaterials would allow the utilisation of read-across approaches and could provide
justiﬁcation for waiving of tests. Although a complex area, particularly for nanomaterials, such approaches have started to be
proposed e.g. [5]. Computational models would also be useful to establish correlations between nanomaterial properties,
toxicokinetics and adverse effects. At the present time these models can complement experimental data, but cannot replace them.
•  Expanding the use of in vitro approaches that are speciﬁcally targeted towards the fulﬁlment of regulatory data requirements. High
throughput systems will also play a key role. They have the potential to provide information on nanomaterial physicochemical
characteristics, hazard and internal exposure for use in risk assessment (as envisioned by the ITS-NANO framework [6]). These
platforms may  also be used as tools more widely in the early screening of candidate nanomaterials. This would help ensure that the
toxicological potential of nanomaterials is detected and better understood prior to them being tested in animal studies [7].
•  Investing further into innovative technologies for nano-speciﬁc use. These often offer the beneﬁt of physiological relevance, e.g.
microﬂuidic systems that can more accurately replicate conditions within a human organ (e.g. the lung [8]).
•  Reﬁnement of necessary in vivo tests should continue within this timeframe. For example, developing short-term studies for routes
other  than inhalation e.g. oral, and improving the technical aspects of inhalation studies.
Long-term (10 years+) • Incorporation of exposure route and internal exposure considerations, by utilising in vitro systems that provide information on
barrier penetration and translocation capabilities. Such systems may  include 3D tissue models, which are more realistic and
physiologically relevant systems than traditional 2D/monolayer methods. An emphasis on using human cells and tissues in these
models where possible will further increase their relevance in human safety assessment.
•  Sufﬁcient acquisition of further mechanistic knowledge on the key events that result in adverse effects at an organism level. This
will  support continued development of adverse outcome pathways (AOPs) speciﬁc for nanomaterials, which can begin now using
currently available knowledge. The AOP framework has potential to identify data gaps and highlight the key aspects of toxicity
pathways that require further investigation. These ﬁndings could then accelerate the development and implementation of
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•  Progression of reliable and advanced in silico
Now is the ideal time to embrace a move towards a more
cientiﬁcally-driven paradigm for nanomaterial safety assessment.
he beneﬁts of this will be (i) prioritisation of efforts to overcome
he challenges associated with moving away from traditional tox-
city testing, and subsequently decreasing the numbers of animals
sed, and (ii) capitalisation on all relevant scientiﬁc and techno-
ogical developments, resulting in a ‘21st century’ approach to
anosafety assessment [1], which is as predictive of the human sit-
ation as possible. Application of the 3Rs principles (replacement,
eﬁnement and reduction of animals) offers a framework in the
hort (0–5 years), medium (5–10 years) and long-term (10+ years)
o support and guide this transition. Further detail can be found in
able 1.
In the short-term, the numbers of nanomaterials requiring
esting in regulatory animal studies could be reduced, and the nec-
ssary animal studies reﬁned (i.e., levels of suffering minimised).
he ﬁrst question that should be asked before embarking on any
esting is whether the nanomaterial is likely to be exposed to
umans. If exposure is not anticipated, for example if it is embedded
ithin a matrix, the nanomaterial would not pose a risk, and thus
egulatory studies could be waived. If exposure is likely, a nano-
aterial’s toxicity could ﬁrst be assessed in shorter, ‘preliminary’
nimal studies (which can be completed within 28 days, as opposedPlease cite this article in press as: N. Burden, et al., The 3Rs as a framewo
Nano Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.06.007
o 90-day long regulatory studies). This preliminary data could give
n early indication of potential effects. A decision could be taken at
his point to halt further development of the nanomaterial, thereby
voiding the longer, resource-intensive studies. If the nanomate-dpoints [9].
ls, through the availability of more hazard, kinetic and physicochemical data.
rial continues into regulatory testing, the preliminary data could
be used to inform the design of these studies. This includes the
selection of dose levels, to ensure that excessively high doses result-
ing in non-speciﬁc toxic effects are avoided. In both preliminary
and regulatory studies the nanomaterial should be administered
through the route most relevant to the human exposure scenario.
Traditionally this would be via inhalation, to reﬂect occupational
exposures. As the potential breadth of nanomaterial applications
increases other routes may  also become relevant, such as inges-
tion or dermal. As much relevant information as possible should be
obtained from any animal study performed. This may  include incor-
poration of additional measurements or analyses, providing they
do not cause additional stress to the animals. This could include
determining effects at both the site of exposure and secondary tar-
get sites. Results of short-term studies could also be used to inform
read-across (see below).
Within the medium-term, further reductions in the number of
regulatory studies needed could be achieved through the wider use
of in vitro assays for screening and prioritisation. These could be
assays already validated for the toxicity testing of traditional chem-
icals (for example, those to assess genotoxicity) with modiﬁcations
where appropriate, or assays that have been speciﬁcally developed
for testing nanomaterials. There is also the prospect of utilisingrk to support a 21st century approach for nanosafety assessment,
unprotected species, such as invertebrates and early-lifestage ﬁsh
embryos. Data from adapted in vitro assays, in combination with
existing in vivo data and the use of computational models, will
also help to identify links between structural, biological or physic-
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chemical properties of nanomaterials and their toxic effects. The
oxicity (or lack of toxicity) of a novel nanomaterial could then
e inferred based on the presence or absence of speciﬁc proper-
ies or combinations of such properties, in a process known as
ead-across. Sufﬁcient conﬁdence in read-across techniques would
bviate the need to assess whether the nanomaterial is toxic within
nimal studies. If such a judgement cannot be conﬁdently made,
he nanomaterial may  then need to be tested in relevant animal
tudies (providing it is not intended for use in a cosmetic prod-
ct). Increased knowledge gained on the release and dispersion
nd uptake of nanomaterials in this timeframe will help to better
nderstand likely levels of human exposure. This will aid in better
etermining the most relevant route of administration for animal
tudies; informing decisions to waive studies; and ensuring that
anomaterials are tested at doses and in models that are reﬂective
f likely human internal doses.
In the long-term, the goal will be the replacement of animal
oxicity studies with more predictive, human-relevant methods,
oupled with high throughput screening to enable rapid and auto-
ated evaluation. This will be supported by the wider utilisation
f human cells and 3D cell models that are more representa-
ive of human tissues compared with traditional cell-based assays.
n vitro systems capable of mimicking physiological processes such
s nanomaterial penetration and metabolism will also be essen-
ial. Increased understanding of the mechanisms and biochemical
athways that lead to toxic effects gained in the coming years will
arrow down which types of biological activity should be exam-
ned within the in vitro assays. Relating the effects observed and
xposure levels in vitro to the human situation will require the
pplication of elegant computational models. It is clear that it
ill not be necessary to generate the same types of data for all
anomaterials, as the needs will be dependent on their intended
pplication and their inherent properties. By nature, in vitro and
n silico methods will not replace the traditional whole organism
ests on a one-for-one basis. Complete replacement will only occur
f all the available information on a nanomaterial is considered and
ntegrated. This also relies on the decision-makers within regula-
ory bodies having conﬁdence in making safety decisions based on
ypes and combinations of data they are not currently familiar with.
There are a number of barriers that will need to be overcome to
nable the transition from the status quo towards complete replace-
ent within the timeframe proposed. Firstly, focused scientiﬁc
ndeavours will be required to ensure that the right tools are avail-
ble and can be successfully harnessed. Key scientiﬁc issues that
emain to be addressed include, but are not limited to, (a) the need
o ensure that new and existing in vitro models are standardised, so
hat the data generated is comparable and of the highest quality;
b) incorporation of the necessary levels of biological and chemical
omplexity within integrated approaches, which also encompass
xposure considerations, and (c) proving that the new approaches
re ﬁt for the purpose they are intended. Secondly, a culture shift is
ecessary towards an environment where non-animal approaches
ecome an integral part of routine risk assessment that is endorsed
y international regulatory agencies. Various global initiatives have
tarted to address some of the issues highlighted here; the biggest
hallenge for the ﬁeld will be ensuring that these, and future efforts,
re co-ordinated and strategically focused.
In summary, application of the 3Rs principles provides a frame-
ork to support and guide the transition towards the vision of a
1st century approach to nanosafety assessment that is exposure-
riven, reduces and replaces animal use, increases the efﬁciency of
he process, and is more human relevant. The points raised herePlease cite this article in press as: N. Burden, et al., The 3Rs as a framewo
Nano Today (2016), http://dx.doi.org/10.1016/j.nantod.2016.06.007
re also applicable to all sectors of the chemicals industry. Gen-
ine change will only happen if regulatory bodies are open about
hich situations they are willing to accept non-traditional data, and
eady to compromise on the current reliance on ‘tried-and-tested’ PRESS
y xxx (2016) xxx–xxx 3
methods of risk assessment. Industry will play a role by specifying
their needs and requirements to help steer future academic and
exploratory research. Such research will only take place if there
is an increase in targeted, strategic funding. The most important
aspect of all to move things forward and achieve the goals set out
here will be open, face-to-face discussion and collaboration, which
incorporates cross-talk between all relevant stakeholders.
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